Rivian Automotive, Inc. / DE RIVN
Deals with insiders in the proxy filed Apr 27, 2026
Proxy, Item 404Deals between RIVN and its directors, executives, owners of more than 5% or their families: a relative on the payroll, a plane the company charters from its CEO, a director's company that buys from it. SEC rules (Item 404) make the company list every such deal over $120,000 in its proxy statement.
New this year
Compared with Apr 29, 2025
Paragraphs about a deal, a person or a relative with nothing like them in the proxy filed Apr 29, 2025.
Policies and Procedures for Related Person Transactions“In 2025, we spun out our micromobility business into a new company, Also, Inc. (“Also”). As of March 31, 2026, we hold a 35.3% ownership interest in Also, and are party to certain agreements, including an Amended and Restated Investors’ Rights Agreement, dated as of July 9, 2025 (the “Also IRA”), by and among the Company, Also and certain other Also stockholders. In addition, Dr. Scaringe, our Founder and Chief Executive Officer, serves as the Chairman of Also’s board of directors.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In December 2025, Also had an opportunity to expand its Series C financing round in order to accommodate a new investment; however, this would have led to additional dilution beyond what was originally contemplated by Also’s existing stockholders. To offset this additional dilution and facilitate the investment, Also and Dr. Scaringe agreed to the repurchase of 1,352,726 shares of Also common stock that were held by Dr. Scaringe (the “Repurchased Options”) at the price per share paid by Series C investors, using a portion of the proceeds from the new investment (the “Option Repurchase”). In order to facilitate the Option Repurchase, Also and Dr. Scaringe also agreed to accelerate the vesting of the Repurchased Options (the “Option Acceleration”). Also solicited our consent pursuant to the Option Repurchase and Option Acceleration pursuant to the terms of the Also IRA. An independent Special Committee of our Board of Directors, formed to oversee the Company’s participation in Also’s financings and other related transactions, reviewed and approved the terms of the Option Repurchase and the Option Acceleration. In connection with the Option Repurchase, Dr. Scaringe received an approximately $23.5 million net cash payment.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In 2025, we formed a new entity focused primarily on industrial robotics, Mind Robotics Inc. As of March 31, 2026, we hold a 37.6% ownership interest in Mind Robotics, Inc., and Dr. Scaringe, our Founder and Chief Executive Officer, serves as the Chairman of Mind Robotics Inc.’s board of directors and Mr. Callahan, our Chief Administrative Officer is a member of the board of directors of Mind Robotics, Inc.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“On November 6, 2025, Mind Robotics, LLC, a subsidiary of Mind Robotics, Inc. (together with Mind Robotics LLC, “Mind Robotics”), issued 1,000,000 common units (the “MR Profits Interest Award”) to Dr. Scaringe in connection with Dr.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“Scaringe’s service as Chairman, with an award date fair value of $14.5 million. See “Compensation Discussion and Analysis - Mind Robotics, LLC Profits Interests” for further information regarding the MR Profits Interest Award. Such issuance was previously approved by a special committee of our Board made up of disinterested and independent directors. The MR Profits Interest Award provides Dr. Scaringe with up to a 10% economic interest in Mind Robotics once the profits and gains at Mind Robotics exceed a certain threshold following the date of issuance of the Profits Interest Award. The MR Profits Interest Award was fully vested on the date of issuance.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In March 2026, Mind Robotics Inc. granted Dr. Scaringe an option to purchase 200,000 shares of common stock of Mind Robotics Inc. at an exercise price per share equal to the fair market value of the common stock as determined by the board of directors of Mind Robotics Inc. (the “MR Option Award”). Such issuance was previously approved by a special committee of our Board made up of disinterested and independent directors. The MR Option Award consists of two tranches of 100,000 shares each, with each tranche vesting upon the achievement of certain financial or operational milestones of Mind Robotics Inc., subject to Dr. Scaringe’s continued service with Mind Robotics Inc. through each such vesting date.”
Read it in the proxyopen_in_new
The whole section
As filed
8 paragraphs quoted as filed
Policies and Procedures for Related Person Transactions“Our Board of Directors has adopted a written Related Person Transaction Policy, setting forth the policies and procedures for the review and approval or ratification of related person transactions. Under the policy, our finance department is primarily responsible for developing and implementing processes and procedures to obtain information regarding related persons with respect to potential related person transactions and then determining, based on the facts and circumstances, whether such potential related person transactions do, in fact, constitute related person transactions requiring compliance with the policy. If our finance department determines that a transaction or relationship is a related person transaction requiring compliance with the policy, our Chief Financial Officer is required to present to the Audit Committee all relevant facts and circumstances relating to the related person transaction. Our Audit Committee must review the relevant facts and circumstances of each related person transaction, including if the transaction is on terms comparable to those that could be obtained in arm’s length dealings with an unrelated third party and the extent of the related person’s interest in the transaction, take into account the conflicts of interest and corporate opportunity provisions of our Code of Business Conduct and Ethics, and either approve or disapprove the related person transaction. If advance Audit Committee approval of a related person transaction requiring the Audit Committee’s approval is not feasible, then the transaction may be preliminarily entered into by management upon prior approval of the transaction by the Chair of the Audit Committee subject to ratification of the transaction by the Audit Committee at the Audit Committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. If a transaction was not initially recognized as a related person transaction, then upon such recognition the transaction will be presented to the Audit Committee for ratification at the Audit Committee’s next regularly scheduled meeting; provided, that if ratification is not forthcoming, management will make all reasonable efforts to cancel or annul the transaction. Our management will update the Audit Committee as to any material changes to any approved or ratified related person transaction and will provide a status report at least annually of all then current related person transactions. No director may participate in approval of a related person transaction for which he or she is a related person.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“The following are certain transactions, arrangements, and relationships with our directors, executive officers, and stockholders owning 5% or more of our outstanding Common Stock, or any member of the immediate family of any of the foregoing persons, since January 1, 2025, other than equity and other compensation, termination, change in control and other arrangements, which are described under “Executive Compensation.””
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In 2025, we spun out our micromobility business into a new company, Also, Inc. (“Also”). As of March 31, 2026, we hold a 35.3% ownership interest in Also, and are party to certain agreements, including an Amended and Restated Investors’ Rights Agreement, dated as of July 9, 2025 (the “Also IRA”), by and among the Company, Also and certain other Also stockholders. In addition, Dr. Scaringe, our Founder and Chief Executive Officer, serves as the Chairman of Also’s board of directors.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In December 2025, Also had an opportunity to expand its Series C financing round in order to accommodate a new investment; however, this would have led to additional dilution beyond what was originally contemplated by Also’s existing stockholders. To offset this additional dilution and facilitate the investment, Also and Dr. Scaringe agreed to the repurchase of 1,352,726 shares of Also common stock that were held by Dr. Scaringe (the “Repurchased Options”) at the price per share paid by Series C investors, using a portion of the proceeds from the new investment (the “Option Repurchase”). In order to facilitate the Option Repurchase, Also and Dr. Scaringe also agreed to accelerate the vesting of the Repurchased Options (the “Option Acceleration”). Also solicited our consent pursuant to the Option Repurchase and Option Acceleration pursuant to the terms of the Also IRA. An independent Special Committee of our Board of Directors, formed to oversee the Company’s participation in Also’s financings and other related transactions, reviewed and approved the terms of the Option Repurchase and the Option Acceleration. In connection with the Option Repurchase, Dr. Scaringe received an approximately $23.5 million net cash payment.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In 2025, we formed a new entity focused primarily on industrial robotics, Mind Robotics Inc. As of March 31, 2026, we hold a 37.6% ownership interest in Mind Robotics, Inc., and Dr. Scaringe, our Founder and Chief Executive Officer, serves as the Chairman of Mind Robotics Inc.’s board of directors and Mr. Callahan, our Chief Administrative Officer is a member of the board of directors of Mind Robotics, Inc.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“On November 6, 2025, Mind Robotics, LLC, a subsidiary of Mind Robotics, Inc. (together with Mind Robotics LLC, “Mind Robotics”), issued 1,000,000 common units (the “MR Profits Interest Award”) to Dr. Scaringe in connection with Dr.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“Scaringe’s service as Chairman, with an award date fair value of $14.5 million. See “Compensation Discussion and Analysis - Mind Robotics, LLC Profits Interests” for further information regarding the MR Profits Interest Award. Such issuance was previously approved by a special committee of our Board made up of disinterested and independent directors. The MR Profits Interest Award provides Dr. Scaringe with up to a 10% economic interest in Mind Robotics once the profits and gains at Mind Robotics exceed a certain threshold following the date of issuance of the Profits Interest Award. The MR Profits Interest Award was fully vested on the date of issuance.”
Read it in the proxyopen_in_new
Policies and Procedures for Related Person Transactions“In March 2026, Mind Robotics Inc. granted Dr. Scaringe an option to purchase 200,000 shares of common stock of Mind Robotics Inc. at an exercise price per share equal to the fair market value of the common stock as determined by the board of directors of Mind Robotics Inc. (the “MR Option Award”). Such issuance was previously approved by a special committee of our Board made up of disinterested and independent directors. The MR Option Award consists of two tranches of 100,000 shares each, with each tranche vesting upon the achievement of certain financial or operational milestones of Mind Robotics Inc., subject to Dr. Scaringe’s continued service with Mind Robotics Inc. through each such vesting date.”
Read it in the proxyopen_in_new
Paragraphs are compared by their words, not read by AI: one counts as new when no paragraph last year shares half of its words, or when it names a person or company last year's section did not. A deal reported again with a new amount is not new. Always check the filing. Open the proxy ↗ · Last year's proxy ↗
Sources
The related-party section (Item 404) of the latest annual proxy statement (DEF 14A), against last year's, compared by their words.
Also
CEO pay: the same proxy's pay versus performance table.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RIVN/export.csv") into a cell.